|
||
Macrophages Control the Retention and Trafficking of B Lymphocytes in the Splenic Marginal Zone
2 Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021
3 Centre d'Immunologie de Marseille Luminy, CNRS-INSERM-Universite de la Mediterranee, 13288 Marseille, France
4 Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Rockville, MD 20852
5 Department of Medical Biochemistry and Biophysics, Division of Matrix Biology, The Karolinska Institute, 17177 Stockholm, Sweden
Address correspondence to Jeffrey V. Ravetch, Laboratory of Molecular Genetics and Immunology, The Rockefeller University, Box 98, 1230 York Avenue, New York, NY 10021. Phone: 212-327-7321; Fax: 212-327-7318; E-mail: ravetch{at}rockefeller.edu
| Abstract |
|---|
|
|
|---|
Key Words: SHIP Btk MARCO migration Staphylococcus aureus
Antibodies and Reagents.
Conditional Targeting of SHIP.
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
Blood-borne pathogens first encounter the adaptive immune system in the marginal zone region of the spleen where the convergence of innate and adaptive immune mechanisms insures an early and effective response to pathogen antigens (1, 2). Both thymic-independent and -dependent responses are elicited in response to infection (1, 3). The thymic-independent response involves the targeting and activation of marginal zone B cells (MZBs)*through their interaction with the repetitive antigenic determinants of pathogens with complement and B cell antigen receptors (4, 5). In contrast, the thymic-dependent Ab response is driven by the interaction and reciprocal stimulation of APCs, T lymphocytes, and B cells. The organization of the splenic white pulp nodule into discrete zones enriched for either B cells, T cells, or APCs provide a spatial microenvironment that facilitates an efficient interaction of pathogens with the various cellular populations required for insuring an efficient immune response (68). Antigen presentation and stimulation of T and B cells ultimately results in the formation of germinal centers, high affinity neutralizing Abs, and memory cells. Recent reports have begun to define the cellular components and molecular signals that are necessary to establish the marginal zone. B cell intrinsic pathways have been described involving specific chemokines and their receptors, molecules involved in B cell activation, as well as adhesion molecules and their ligands (9, 10). Apart from the MZB, the other predominant cell of the marginal zone is the marginal zone macrophage (MZMO), which is distinct from the metallophilic macrophage, defined by the marker MOMA-1, located at the border of the marginal and follicular zone (11). The MZMO is defined by its location, interspersed in several layers within the marginal zone, and by its expression of the markers MARCO and ER-TR9 (12, 13). The former molecule is a scavenger receptor belonging structurally to the class A receptor family whereas the latter is identical to the C-type lectin SIGN-RI (1417). MARCO has been shown to bind a range of microbial Ags including Staphylococcus aureus and Escherichia coli whereas SIGN-RI is the predominant receptor for uptake of polysaccharide dextran by MZMOs. Even though both MZBs and MZMOs are implicated in both thymus-dependent and -independent immune responses, the exact roles of the two cell types in initiation of the response to blood-borne pathogens is not known. We now define a unique role for the MZMO in regulation of MZB retention and activation and show that movement of this subset of macrophages to the red pulp of the spleen involves signaling via SH2-containing inositol-5-phosphatase 1 (SHIP) and Bruton's tyrosine kinase (Btk). In addition, we show a direct interaction between MZMOs and MZBs via the MARCO receptor on MZMOs and a ligand on MZBs.
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
Mice.
C57BL/6 mice obtained from The Jackson Laboratory were used as WT mice and controls unless otherwise stated. Founders of SHIP-deficient mice were provided by G. Krystal (Terry Fox Laboratory, BC Cancer Agency, Vancouver, Canada; reference 18) and Btk-deficient mice were purchased from The Jackson Laboratory. Op/op mice were provided by J. Pollard (Albert Einstein College of Medicine, New York, NY) and LysMCre transgenic mice (19) were provided by I. Forster (Technical University of Munich, Germany). Abs and bacteria was injected i.v. in the tail vein and all experiments involving mice were performed in accordance with National Institutes of Health (NIH) guidelines. All mice were maintained under specific pathogen-free conditions at The Rockefeller University.
For histological examination 6-µM frozen sections were stained, and for FACS® analysis erythrocyte-depleted spleen cells were used. Macrophages were detected using MOMA-1, MARCO Abs from Serotec, and ER-TR9 from Accurate Chemical & Scientific Corp. Abs to CD1d, B220, CD19, CD21/CD35 (CRI/II), CD23, MAC-1, antirat alkaline phosphatase, and antirabbit horseradish peroxidase were from BD Biosciences. Secondary Abs for immunohistochemistry, anti-biotin, anti-FITC F(ab') horseradish peroxidase, or alkaline phosphatase were from DakoCytomation and rabbit antiSHIP used for Western blot was from Upstate Biotechnology. Vector Blue Alkaline Phosphatase Substrate from Vector Laboratories and DAB peroxidase substrate from Sigma-Aldrich were used for development of immunohistochemistry stains. Soluble MARCO receptor was provided by T. Pikkarainen (The Karolinska Institute, Stockholm, Sweden; reference 20) and was biotinylated using the EZ-LinkTM kit from Pierce Chemical Co. The biotinylated soluble MARCO was detected using Streptavidin-CyChromeTM from BD Biosciences. S. aureus fluorescent bioparticles were purchased from Molecular Probes, Inc. and MACS anti-FITC and anti-biotin beads were from Miltenyi Biotec. Cl2MDP (or clodronate) and PBS liposomes were provided by Roche Diagnostics.
Floxed SHIP mice were created by insertion of loxP sites flanking the 10th and 11th exons (see Fig. 2 a) of the SHIP gene. The targeting vector was introduced into embryonic stem (ES) cells by electroporation and clones were selected with neomycin and ganciclovir and verified by Southern blot and PCR. Properly integrated ES clones were transiently transfected with a Cre-expressing plasmid. Clones were subsequently selected for a conditional floxed allele (SHIPflox) or null allele (SHIPnull) using Southern blot and PCR. Appropriate ES clones were then injected into blastocysts to generate chimeric mice. The chimeric mice were then bred with C57BL/6 mice to achieve germline transmission. These mice were subsequently crossed with mice expressing Cre in the myeloid compartment (LysMcre; reference 19) to generate Cre+/null/flox mice. Mice were screened for respective genotype by PCR and SHIP protein expression using Western blot (21) on equal numbers of spleen cells purified by MACS (Miltenyi Biotec) sorting according to protocol from the manufacturer. Relative expression of SHIP in macrophage and B cell populations (comparing wt/null with flox/null/cre) were estimated using Alpha imager software from Alpha Innotech Corp.
![]()
Results and Discussion
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
Mice deficient in the inhibitory signaling molecule SHIP display pleiotropic defects in macrophages, NK cells, and lymphocytes (18, 22). A prominent feature of these mice is their splenomegaly resulting from dysregulation of myeloid proliferation. As seen in Fig. 1
, SHIP-deficient mice also display a specific defect in the organization of the splenic follicle with the loss of MZBs measured as the CD21high/CD23low population in FACS® and in sections as the B220+ cells localizing peripherally to the MOMA-1+ cells (Fig. 1, a and b). In the SHIP-deficient mice the MARCO+ MZMO cells are no longer organized within the marginal zone and adjacent to the MOMA-1 macrophages but are redistributed to the red pulp, whereas MOMA-1+ metallophils remain unaffected (Fig. 1 b). Because SHIP is expressed in most hematopoietic cells, including lymphoid and myeloid subsets, we determined if this marginal zone phenotype in SHIP-deficient mice was the result of primary macrophage dysregulation. A conditional disruption of SHIP was generated in which macrophages displayed an approximate >90% reduction in SHIP expression whereas B cell expression was reduced by <10% (Fig. 2
, a and b). This is consistent with the expression patterns of Cre recombinase, driven by the lysosyme promoter used (19). The mice developed a splenomegaly at
5 wk of age (Fig. 2 b), similar to that of complete SHIP deletion, thus implicating a primary macrophage defect as the cause for splenomegaly in SHIP-/- mice (18). In addition, the mice displayed essentially the same marginal zone phenotype with significantly reduced MZBs as defined by flow cytometry and reorganization of the MZMOs as observed by histological staining (Fig. 2 c). To confirm that the SHIP phenotype is B cell nonautonomous and that SHIP-deficient B cells can give rise to MZB populations when WT MZMOs are available, we produced BM chimeras using SHIP-deficient BM combined with WT BM and injected these cells into irradiated WT recipients. In the resulting chimeric mice the SHIP-deficient and WT BMs contributed equally to the MZB population (unpublished data).
|
|
|
|
|
|
|
|
4ß1 because disruption of that pathway with antibodies to LFA-1 and
4ß1 results in the release of MZBs to the blood stream (9), not their migration into the follicle, in contrast to the results presented here (Fig. 8). In addition, we see no effect on the localization of MZMO cells using antibodies to the stromal integrins, nor do we observe effects on their ligand expression when MZMO cells are triggered to migrate (unpublished data). These pathways are thus likely to serve different functions in the organization of the marginal zone, with the MZMO pathway specific for the antimicrobial response, leading to internalization of the organism and trafficking of B cells into the follicular zone to propagate the immune responses. MZBs have the capacity to bind polysaccharide Ags through complement-mediated pathways and transport these to the follicular area of the spleen (6, 8, 42). The events we have described appear to be another mechanism for delivery of MZBs and Ag to the T cellrich follicular region. MZBs have mostly been implicated in the response to T cellindependent Ags, however, they are also capable of presenting Ags (43) and may thus be important both for the T celldependent and independent phase of the earliest defense against a pathogen. | Acknowledgments |
|---|
This work was supported by the Swedish Cancer Society and the NIH.
Submitted: April 25, 2003
Revised: April 25, 2003
Accepted: May 20, 2003
| Footnotes |
|---|
| References |
|---|
|
|
|---|
1 Martin, F., and J.F. Kearney. 2002. Marginal-zone B cells. Nat. Rev. Immunol. 2:323335.[CrossRef][Medline]
2 Kraal, G. 1992. Cells in the marginal zone of the spleen. Int. Rev. Cytol. 132:3174.[Medline]
3 Fagarasan, S., and T. Honjo. 2000. T-Independent immune response: new aspects of B cell biology. Science. 290:8992.
4 Garcia de Vinuesa, C., P. O'Leary, D.M. Sze, K.M. Toellner, and I.C. MacLennan. 1999. T-independent type 2 antigens induce B cell proliferation in multiple splenic sites, but exponential growth is confined to extrafollicular foci. Eur. J. Immunol. 29:13141323.[CrossRef][Medline]
5 Guinamard, R., M. Okigaki, J. Schlessinger, and J.V. Ravetch. 2000. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat. Immunol. 1:3136.[CrossRef][Medline]
6 Pozdnyakova, O., H.K. Guttormsen, F.N. Lalani, M.C. Carroll, and D.L. Kasper. 2003. Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J. Immunol. 170:8490.
7 Zandvoort, A., and W. Timens. 2002. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin. Exp. Immunol. 130:411.[CrossRef][Medline]
8 Gray, D., D.S. Kumararatne, J. Lortan, M. Khan, and I.C. MacLennan. 1984. Relation of intra-splenic migration of marginal zone B cells to antigen localization on follicular dendritic cells. Immunology. 52:659669.[Medline]
9 Lu, T.T., and J.G. Cyster. 2002. Integrin-mediated long-term B cell retention in the splenic marginal zone. Science. 297:409412.
10 Balazs, M., F. Martin, T. Zhou, and J. Kearney. 2002. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity. 17:341352.[CrossRef][Medline]
11 Kraal, G., and M. Janse. 1986. Marginal metallophilic cells of the mouse spleen identified by a monoclonal antibody. Immunology. 58:665669.[Medline]
12 Elomaa, O., M. Kangas, C. Sahlberg, J. Tuukkanen, R. Sormunen, A. Liakka, I. Thesleff, G. Kraal, and K. Tryggvason. 1995. Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell. 80:603609.[CrossRef][Medline]
13 Dijkstra, C.D., E. Van Vliet, E.A. Dopp, A.A. van der Lelij, and G. Kraal. 1985. Marginal zone macrophages identified by a monoclonal antibody: characterization of immuno- and enzyme-histochemical properties and functional capacities. Immunology. 55:2330.[Medline]
14 Kang, Y.S., S. Yamazaki, T. Iyoda, M. Pack, S.A. Bruening, J.Y. Kim, K. Takahara, K. Inaba, R.M. Steinman, and C.G. Park. 2003. SIGN-R1, a novel C-type lectin expressed by marginal zone macrophages in spleen, mediates uptake of the polysaccharide dextran. Int. Immunol. 15:177186.
15 Geijtenbeek, T.B., P.C. Groot, M.A. Nolte, S.J. van Vliet, S.T. Gangaram-Panday, G.C. van Duijnhoven, G. Kraal, A.J. van Oosterhout, and Y. van Kooyk. 2002. Marginal zone macrophages express a murine homologue of DC-SIGN that captures blood-borne antigens in vivo. Blood. 100:29082916.
16 Park, C.G., K. Takahara, E. Umemoto, Y. Yashima, K. Matsubara, Y. Matsuda, B.E. Clausen, K. Inaba, and R.M. Steinman. 2001. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int. Immunol. 13:12831290.
17 Leenen, P.J., M.F. de Bruijn, J.S. Voerman, P.A. Campbell, and W. van Ewijk. 1994. Markers of mouse macrophage development detected by monoclonal antibodies. J. Immunol. Methods. 174:519.[CrossRef][Medline]
18 Helgason, C.D., J.E. Damen, P. Rosten, R. Grewal, P. Sorensen, S.M. Chappel, A. Borowski, F. Jirik, G. Krystal, and R.K. Humphries. 1998. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12:16101620.
19 Clausen, B.E., C. Burkhardt, W. Reith, R. Renkawitz, and I. Forster. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8:265277.[CrossRef][Medline]
20 Sankala, M., A. Brannstrom, T. Schulthess, U. Bergmann, E. Morgunova, J. Engel, K. Tryggvason, and T. Pikkarainen. 2002. Characterization of recombinant soluble macrophage scavenger receptor MARCO. J. Biol. Chem. 277:3337833385.
21 Ono, M., H. Okada, S. Bolland, S. Yanagi, T. Kurosaki, and J.V. Ravetch. 1997. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell. 90:293301.[CrossRef][Medline]
22 Wang, J.W., J.M. Howson, T. Ghansah, C. Desponts, J.M. Ninos, S.L. May, K.H. Nguyen, N. Toyama-Sorimachi, and W.G. Kerr. 2002. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science. 295:20942097.
23 Tsukada, S., D.J. Rawlings, and O.N. Witte. 1994. Role of Bruton's tyrosine kinase in immunodeficiency. Curr. Opin. Immunol. 6:623630.[CrossRef][Medline]
24 Bolland, S., R.N. Pearse, T. Kurosaki, and J.V. Ravetch. 1998. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity. 8:509516.[CrossRef][Medline]
25 Mukhopadhyay, S., M. Mohanty, A. Mangla, A. George, V. Bal, S. Rath, and B. Ravindran. 2002. Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance. J. Immunol. 168:29142921.
26 Satterthwaite, A.B., C.A. Lowell, W.N. Khan, P. Sideras, F.W. Alt, and O.N. Witte. 1998. Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways. J. Exp. Med. 188:833844.
27 Smith, C.I., T.C. Islam, P.T. Mattsson, A.J. Mohamed, B.F. Nore, and M. Vihinen. 2001. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays. 23:436446.[CrossRef][Medline]
28 Weil, D., M.A. Power, S.I. Smith, and C.L. Li. 1997. Predominant expression of murine Bmx tyrosine kinase in the granulo-monocytic lineage. Blood. 90:43324340.
29 Tomlinson, M.G., T. Kurosaki, A.E. Berson, G.H. Fujii, J.A. Johnston, and J.B. Bolen. 1999. Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk. J. Biol. Chem. 274:1357713585.
30 Buiting, A.M., Z. de Rover, E. Claassen, and N. van Rooijen. 1993. In vivo distribution of particulate antigens and liposomes in murine spleen. A possible role in the humoral immune response. Immunobiology. 188:1322.[Medline]
31 Ito, S., M. Naito, Y. Kobayashi, H. Takatsuka, S. Jiang, H. Usuda, H. Umezu, G. Hasegawa, M. Arakawa, L.D. Shultz, et al. 1999. Roles of a macrophage receptor with collagenous structure (MARCO) in host defense and heterogeneity of splenic marginal zone macrophages. Arch. Histol. Cytol. 62:8395.[CrossRef][Medline]
32 Takahashi, K., S. Umeda, L.D. Shultz, S. Hayashi, and S. Nishikawa. 1994. Effects of macrophage colony-stimulating factor (M-CSF) on the development, differentiation, and maturation of marginal metallophilic macrophages and marginal zone macrophages in the spleen of osteopetrosis (op) mutant mice lacking functional M-CSF activity. J. Leukoc. Biol. 55:581588.[Abstract]
33 Van der Laan, L.J., E.A. Dopp, R. Haworth, T. Pikkarainen, M. Kangas, O. Elomaa, C.D. Dijkstra, S. Gordon, K. Tryggvason, and G. Kraal. 1999. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J. Immunol. 162:939947.
34 Yokota, T., B. Ehlin-Henriksson, and G.K. Hansson. 1998. Scavenger receptors mediate adhesion of activated B lymphocytes. Exp. Cell Res. 239:1622.[CrossRef][Medline]
35 Gebe, J.A., M. Llewellyn, H. Hoggatt, and A. Aruffo. 2000. Molecular cloning, genomic organization and cell-binding characteristics of mouse Sp
. Immunology. 99:7886.[CrossRef][Medline]
36 Kotani, M., K. Matsuno, K. Miyakawa, T. Ezaki, T. Hayama, and S. Ekino. 1985. Migration of macrophages from the marginal zone to germinal centers in the spleen of mice. Anat. Rec. 212:172178.[CrossRef][Medline]
37 Groeneveld, P.H., T. Erich, and G. Kraal. 1986. The differential effects of bacterial lipopolysaccharide (LPS) on splenic non-lymphoid cells demonstrated by monoclonal antibodies. Immunology. 58:285290.[Medline]
38 Smith, K.G., T.D. Hewitson, G.J. Nossal, and D.M. Tarlinton. 1996. The phenotype and fate of the antibody-forming cells of the splenic foci. Eur. J. Immunol. 26:444448.[Medline]
39 Ho, F., J.E. Lortan, I.C. MacLennan, and M. Khan. 1986. Distinct short-lived and long-lived antibody-producing cell populations. Eur. J. Immunol. 16:12971301.[Medline]
40 Sze, D.M., K.M. Toellner, C. Garcia de Vinuesa, D.R. Taylor, and I.C. MacLennan. 2000. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J. Exp. Med. 192:813821.
41 Vieira, O.V., R.J. Botelho, and S. Grinstein. 2002. Phagosome maturation: aging gracefully. Biochem. J. 366:689704.[CrossRef][Medline]
42 Guinamard, R., N. Signoret, I. Masamichi, M. Marsh, T. Kurosaki, and J.V. Ravetch. 1999. B cell antigen receptor engagement inhibits stromal cellderived factor (SDF)-1
chemotaxis and promotes protein kinase C (PKC)-induced internalization of CXCR4. J. Exp. Med. 189:14611466.
43 Oliver, A.M., F. Martin, and J.F. Kearney. 1999. IgMhigh CD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J. Immunol. 162:71987207.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|